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Abstract: Oncology treatment-related diarrhea and malnutrition appear together in oncological
patients because of the disease itself, or the treatments that are administered for it. Therefore it
is essential to carry out a nutritional treatment. Enteral nutrition formulas, containing peptides
and medium chain triglycerides, can facilitate absorption in cases of malabsorption. There are few
references to the use of enteral nutrition in the clinical society guidelines of patient management with
oncology treatment-related diarrhea (OTRD). A bibliographic review of the studies with oligomeric
enteral nutrition in OTRD found only nine studies with chemotherapy (all with the same oligomeric
formula in which oral mucositis improves, while the rest of the outcomes show different results),
and eight studies with radiotherapy (with different products and very heterogeneous results). We
hereby present our action algorithm to supplement the diet of OTRD patients with an oligomeric
enteral nutrition formula. The first step is the nutritional assessment, followed by the assessment of
the functional capacity of the patient’s intestine. With these two aspects evaluated, the therapeutic
possibilities available vary in degrees of complexity: These will range from the usual dietary
recommendations, to supplementation with oral oligomeric enteral nutrition, along with complete
enteral nutrition with oligomeric formula, and up to potentially total parenteral nutrition.
Keywords: oncology treatment related diarrhea; review; nutritional algorithm; oligomeric enteral
nutrition formula
1. Introduction
In the recent years there have been substantial advances in molecularly-targeted therapies for the
treatment of patients with cancer. However, chemotherapy and radiotherapy are continuously used
alone, combined, or utilized even before surgery. Chemo-radiotherapy causes and even exacerbates a
symptom that worsens the nutritional status of our patients, which symptom is caused by digestive
toxicity, such as nausea, vomiting, mucositis and diarrhea.
Diarrhea and malnutrition appear together in the oncological patient as a consequence of the
disease itself, or because of the administered treatments. Chemotherapy and radiotherapy cause
different undesirable effects on the gastrointestinal tract mucosa, like inflammation, edema, ulceration
and atrophy. The increase in mucosal permeability, combined with immunosuppression, predisposes
the patient to bacterial translocations, septicemia and ischemia [1].
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The most serious complications by chemotherapy include myelosuppression, hepatic or renal
disorder, oral mucositis or diarrhea. However, prevention methods have not yet been well established.
On the other hand, treatment with radiotherapy causes radiation-induced enteritis (inflammation of
the small intestine)—when applied directly to the abdominal and pelvic regions in the treatment of
urological, gynecological or gastrointestinal tumors. The small intestine is the most sensitive organ to
radiation. Studies show that 50–75% of patients under study develop mild to severe enteritis after
pelvic or abdominal radiation therapy [2]. Chronic radiation enteritis has been reported in up to 20%
of patients receiving pelvic radiotherapy; with intestinal failure developing in approximately 5% [3].
Radiotherapy of the head and neck or pelvic region is associated with gastrointestinal symptoms and
weight loss in up to 80% of patients.
Oncology treatment-related diarrhea (OTRD) is one the most important manifestations of mucositis
induced by chemotherapy. The exact objective incidence of OTRD may not be well known, because
its incidence is described according to patient complaints, and is often assessed by non-medical staff;
thus, its incidence may often be underestimated. Several studies estimate that approximately 10% of
patients with advanced cancer will present it, with colorectal cancer being the most frequent. Other
authors report that between 20% and 40% of all patients with chemotherapy suffer severe diarrhea [4,5].
In randomized phase III trials, these agents are associated with diarrhea in 50–80% of patients, when
used alone or in combination [6].
In recent years, other agents have been incorporated as oncology treatments that have direct
consequences on a patient’s digestive function, for example: Tirosin-multikinase inhibitors Ssorafenib,
Lenvatinib, Iimatinib, Sunitinib, Pazopanib and Cabozantinib). Many of them display new indications
in several cancer subtypes, such as clear cell carcinoma, hepatocarcinoma, gastrointestinal stromal
tumors, thyroid cancer and lung cancer. In most cases, diarrhea is the main and most common adverse
event. Since those treatments are often administered chronically, long-term control and care of this
problem and its consequences on nutritional status is mandatory [7]. Besides, in the last few years,
immunotherapy has emerged as common new treatments in many other tumors, and once again
diarrhea is a common adverse event whose control and treatment is going to be crucial in order be able
to maintain them in long-term use [8].
Among the most frequent OTRD complications are: Dehydration, electrolyte loss, inadequate
absorption of fats, lactose, bile salts and vitamins, social and personal problems, a reduction of
treatment dose or discontinuation, an alteration of the intestinal flora, hemodynamic instability in
critical patients and malnutrition. This represents a double declining slope: Clinical and economic,
both contributing to reducing survival rates [9].
Many of these side effects of OTRD are associated with malnutrition. Nutritional disorders often
occur in cancer patients because of treatments, or by being related to cancer itself, and thus exacerbate
the complications and adverse effects from cancer treatments. OTRD typically leads to discomfort
and/or pain, which in turn may lead to less food intake and greater susceptibility to infections. Diarrhea,
anorexia and nutritional disorder are three highly correlated factors, and form a vicious circle as an
adverse effect caused by chemotherapy [10].
The published prevalence of malnutrition could vary due to the different identification of
malnutrition definitions, but also because of the tumor’s location and the therapy’s intensity. We
can find a prevalence of malnutrition before the start of cancer therapy between 3–52%. During
radiotherapy and chemotherapy, this percentage of malnourished patients rises to 44–88% [9]. The
prevalence of diarrhea with new agents is variable; for example, it was measured around 53% with
anti-EGFR TKI agents [11], 27–54% with anti-CTLA-4 therapy [12] and 33–49% with the tyrosine kinase
inhibitor Imatinib [13].
It is recognized that malnutrition is associated with lower physical functioning, lower immune
status, more severe late radiotherapy-induced toxicities, treatment interruptions and delayed,
lower chemotherapy response rates, hospital readmissions, impaired quality of life, and increased
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mortality [14]. Therefore, it is important to prevent, recognize and treat malnutrition in an early phase
of oncology treatment.
Regardless of the cause of the OTRD, it is essential to carry out a nutritional treatment that facilitates
absorption, reduces waste and digestive symptoms and contributes to the prevention of malnutrition,
which is so frequent in the oncological population. The approach of malnutrition prevention in
this situation is critical to enable the patient to withstand prolonged oncological treatments. In
patients with clinical stability and a functioning bowel, enteral nutrition can be a valid alternative to
parenteral nutrition. Enteral nutrition exerts a trophic effect upon the intestinal mucosa, and improves
the hepatotrophic and splanchnic flow [15]. In this way, oral enteral nutrition during oncotherapy
enhances dietary intake, prevents weight loss and promotes adherence to radiotherapy [16]. In patients
with cancer, parenteral nutrition has not been shown to prolong the survival of patients, and even
increases the prevalence of complications compared to enteral nutrition [17].
There are different types of enteral nutrition formulas, which can be classified by their composition.
The European Society for Clinical Nutrition and Metabolism (ESPEN) guidelines on the definitions and
terminology of clinical nutrition affirm “formulas containing peptides and medium chain triglycerides
can facilitate absorption in case of, e.g., malabsorption or short bowel syndrome” [18].
Despite its obvious usefulness, there are few references to the use of enteral nutrition in the
algorithms of patient management with OTRD. This article´s objective of introducing our algorithm is
organized into three parts: Firstly, we review of the main clinical practice guidelines for the treatment
of OTRD nutritional recommendations to assess the role that is attributed to enteral nutrition in their
algorithms. Secondly, we carried out a bibliographic review on the studies with oligomeric enteral
nutrition, in patients with OTRD. Finally, we present our action algorithm to supplement the diet of
patients with OTRD with an oligomeric enteral nutrition formula.
2. Clinical Practice Guidelines for the Management of OTRD
OTRD management standards guidelines are widely published and state that their main aim
should be to reduce the volume of diarrhea, treat dehydration aggressively, and to use drugs if
symptoms persist [19–37].
In general, all guidelines recommend that an early intervention should be performed when the
patient initiates oncological treatment to prevent the progression of the severity of diarrhea. The
treatment to be performed will depend upon the degree of the severity of the diarrhea, as well as the
presence of other risk factors: Fever, vomiting, neutropenia, frank bleeding in the stool, moderate/severe
abdominal pain, and dehydration. Patients with mild diarrhea and without risk factors can be treated
on an outpatient basis with oral antidiarrheal and pharmacological measures, while those with severe
diarrhea and/or risk factors will need in-patient treatment.
Although an adequate intake of fluids and early nutritional recommendations can reduce the
incidence and severity of diarrhea, there are few specific recommendations in the guidelines we have
found. They focus primarily on pharmacological treatment and on ruling out secondary processes that
may be causing infectious diarrhea, medication, obstruction, or concurrent diseases, such as diabetes
mellitus, hyperthyroidism, pancreatic insufficiency, inflammatory bowel disease.
Table 1 summarizes the dietary recommendations of the main international scientific societies [19–37].
All guidelines recommend an increase liquid consumption to avoid dehydration (3–4 L, with a high
sodium content, such as sports drinks, broths, soups, etc.). Some societies also recommend the intake
of foods rich in potassium, such as fruit juices and nectars, sports drinks, potatoes with skin and
plantains [29,38,39]. In addition, in order of the higher to lower frequency of appearance in the guidelines,
we found: Avoid the intake of alcohol and products with caffeine [20–26,29–31,33,34,37,38,40,41], spicy
and fried foods [19,23,25,26,30,33,34,38,41], a low fat diet [19,21–23,26,31,32,38], and small but frequent
meals [20,23,24,26,28,38,40].
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Table 1. Clinical Practice Guidelines for the management of oncology treatment-related diarrhea (OTRD).
Author, Year Oral HidratatIon LowF LowFiber
Soluble
Fiber
Small,
Frequent
Meals
Avoid
Spicy,
Fried
Foods
Avoid
Insoluble
Fiber
Avoid Very Hot or
Cold Foods/Fluids
Avoid
Sorbitol-coNtaining
Substances
Avoid Alcohol,
Caffeine
Limiting
Lactose-coNtaining
Products
Enteralor ParenteraLnutrition
Saltz, LB (2003) [19] 3–4 L water, clear soup,noncarbonated soft drinks x x x x x
Supplementation with the amino acid
glutamine
Benson, Al B. (artículo especial)
(2004) [20] 8–10 glasses of clear liquids at day x x x x Avoid high-osmolar supplements
Canadian Working Group (2007)
[21] Hydration oral x x x
Lupiañez Y. (2008). [22] Fluids noncarbonated, nor irritants x x x x x Indicated in diarrhea (oligomericformula)
BC Cancer Agency (2010) [23] 10–12 cups of fluids throughout theday x x x x x x x x x x
May be indicated in GRADE 3 or 4
diarrhea
Stein, A (2010) [24] Drink 8–10 large glasses of clearliquids a day (eg, Gatorade or broth) x x x
Pan Birmingham Cancer Network
(2012) [25] Drink plenty of fluids. x x x x
Temporarily to see
if this improves
symptoms
Shaw, C (2012) [26] three to four liters of fluid per day x x x x
Wedlake, L.J. (2013) [27]
should
not be
recommended
should
not be
recommended
Should not be
recommended
Total replacement of diet with
elemental formula may be
appropriate in severe toxicity.
McQuade, RM (2014) [28] Drink 8–10 large glasses of clearliquids a day x x
Andreyev, J (2014) [29]
Five sachets in 1 L water (consider
8–10 sachets in 1 L is for replacing
electrolyte deficits)
x
Especially if the
diarrhea is
accompanied by
marked bloating
ESMO Clinical Practice
Guidelines (2015) [30] x x x
Probiotics to prevent diarrhea in a
pelvic malignancy
North of Scotland Cancer Network
(2015) [31] Increase oral fluids (2–3 L per day), x x x x x
Oxford University hospital NHS
foundation trust (2015) [32] Fluids appropriate for weight/age x
Grabenbauer, G (2016) [33] x x x
Enteral nutrition with severe
malnutrition or no enteral food intake
for >7 days or insufficient intake
Mardas, M. (2017) [34] Fluids isotonic x x x x x x x Avoid high osmolar dietarysupplements
Ecancer medical science (2017) [35] Fluids
Thompson, KL (2017) [36] Hydration oral Dietary supplements containing EPAor MFS (fish oil), glutamic, vitamins
Karin, J. (2017) [37] High fluid intake x x x
PDQ Supportive and Palliative
Care. NCI (2018) [38]
Liquid intake to at least 3 L per day
(e.g., water, sports drinks..)avoid
beverages.
x x x x x x x x x x
Thomsen, M (2018) [39] Fluids Activated charcoal, glutamine, andprobiotics
Oncolink (2018) [40] 8–10 glasses of clear liquids per day x x x x
ESMO Clinical Practice
Guidelines (2018) [41]
Diluted fruit juices and flavored soft
drinks along with saltine crackers
and broths or soups
x x x There is insufficientevidence
Glutamine and omega fatty acids.
Requires more studies.
Low fiber diet (e.g., white rice and bread, applesauce); Soluble fiber (e.g., fruits and vegetables without skins, oat bran, barley); Insoluble fiber (e.g., skins of fruits and vegetables,
wholegrain and multigrain foods).
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Other recommendations appear infrequently because they are logical, such as avoiding very hot
or cold foods and fluids [23,30,33,38], or products that contain sorbitol [23,34,38,40].
Regarding the fiber content of the diet, eight out of the twenty-three reviewed guides recommend a
poor fiber diet [19,20,22,23,25,31,34,38], some specify that insoluble fiber should be avoided [19,23,25,31,38],
and others recommend increasing the intake of soluble fiber [22,23,34,37,38].
The intake limitation of products containing lactose is one of the most frequently found
recommendations (fourteen out of the twenty-three reviewed) [19–25,28,29,31,34,37,38,40], despite the
recent European Society for Medical Oncology (ESMO) Clinical Practice Guidelines, which indicate
that there is not enough evidence to avoid lactose in the diet of these patients [41].
It is striking that most of the treatments that appear in the guidelines are focused upon diarrhea,
but very few consider the adequate nutritional support to avoid malnutrition. Diarrhea is associated
with loss of water and electrolytes, but also with nutrient malabsorption. Oncological patients are
susceptible to a high risk of malnutrition due to cancer anorexia-cachexia syndrome, the oncological
treatment toxicity, cancer-associated digestive dysfunction, psychological factors, etc. The appear-ance
of diarrhea in these types of patient substantially worsens their quality of life [10,14].
Nutritional counseling and oral nutritional supplements should be used to increase dietary intake
and to prevent oncology-therapy-associated weight loss and interruption of cancer therapy [42]. ESPEN
expert group recommendations for action against cancer-related malnutrition press the point that
patients with cancer are at particularly high risk for malnutrition, both because of the disease and its
treatments. Furthermore, the deaths of 10–20% of patients with cancer can be attributed to malnutrition,
rather than to the malignancy itself. Nutrition counselling by a health care professional is regarded as
the first line of nutrition therapy [15]. Ravasco et al. [43] observe that nutritional therapy provided an
early and timely individualized nutritional counseling, and that education has a sustained effect upon
outcomes, nutritional intake and status, late radiotherapy toxicity, quality of life and prognosis.
Certain guidelines recommend the use of some type of enteral nutrition
treatment [19,22,23,27,33,36,39,41]. The majority refers to the contribution of glutamine [19,36,39,41],
probiotics [30,39] and omega 3 fatty acids [36,41], although the recent ESMO Clinical Practice
Guidelines [41] indicate that more studies are required to advise its use. With regard to the contribution
of nutritional supplements, some only indicate that products with high osmolality should be
avoided [20,34], others that these supplements should only be used in severe degrees of diarrhea [23]
or in severe malnutrition [33], but only two guides refer to the use of oligomeric formulas [22,27].
It has been suggested that an oligomeric diet might be protective to the intestinal mucosa when
administered to patients with diarrhea associated with oncotherapy. Polymeric enteral nutrition is the
usual type of formula used in patients who need nutritional enteral support, but some patients could
need alternative formulas because of severe diarrhea. Choice of oligomeric enteral formula may be
important to improve nutrients’ absorption and to achieve the goal of the successful completion of
scheduled nutrition and a smooth transition to the normal diet [44].
The polymeric enteral formula contains nitrogen in the form of whole proteins and needs the
gastrointestinal tract digestion process. On the other hand, the nitrogen sources of oligomeric enteral
formula are hydrolyzed proteins (oligopeptides of varying lengths, dipeptides and tripeptides).
These peptides of oligomeric enteral formulas have specific uptake transport mechanisms and are
thought to be absorbed more efficiently than whole proteins. Given impaired digestive function in
cancer patients with diarrhea associated with systemic treatment, oligomeric enteral formulas place
less burden on the digestive system and are absorbed better, and thus are thought to be more favorable
options compared with polymeric formulas [18].
Data from convincing animal experiments and human preclinical studies report reduced pancreatic
or biliary stimulation with oligomeric formula diet, compared to a regular or polymeric diet [45].
Protein is provided as free amino acids or peptides, which reduces the requirement for enzymatic
hydrolysis before absorption, and reduces the risk of presenting an ‘antigenic’ load. The provision of
fats as medium chain triacylglycerol allows their absorption directly into portal blood without the need
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for enzymatic hydrolysis and emulsification by bile salts. Thus, oligomeric formulae can be valuable
therapies in Crohn’s disease [46], and help maintain gut integrity by delivering a readily-available
source of nutrients directly to the gastrointestinal mucosa. Moreover, oligomeric enteral nutrition was
shown to reduce the mucosal production of pro-inflammatory cytokines such as tumor necrosis factor
(TNF)-alpha and interleukin (IL)-6 in patients with Crohn’s disease, and dietary histidine ameliorates
murine colitis by an inhibition of pro-inflammatory cytokine production in macrophages [47].
Mucosal injury is a common oncological treatments side effect, resulting in symptoms of stomatitis
and diarrhea. The mucosal injury causes impaired absorption and eating disorder in addition to pain
associated with the bleeding and ulceration, resulting in increased healthcare costs and an impaired
quality of life [48].
Oligomeric enteral nutrition formulas could help to maintain mucosal integrity in the
gastrointestinal tract, thereby resulting in maintained nutrient absorption. The pathogenic mechanism
underlying gastrointestinal mucosal injury caused by anticancer therapies involves damage in the
DNAs of normal mucosal epithelial cells and fibroblast cells, resulting in suppressed cell growth and
tissue repair. Kawashima et al. [49] investigated the effects of oral supplementation with oligomeric
enteral nutrition diet on mucin in 5-fluorouracil-induced intestinal mucositis. The results of their
studies show that the length of the intestinal tract, dry weight and villus height were reduced by
5-fluorouracil administration. Those animals receiving an oligomeric enteral nutrition diet showed
an improvement in digestive and absorptive function. The authors conclude that oligomeric enteral
nutrition has the ability to improve the intestinal tract defense function mainly exerted through small
intestinal mucin, indicating the possibility of relieving gastrointestinal mucosal injury caused as an
adverse effect of anticancer drugs.
Supported by these studies, we infer that the use of nutritional supplements with oligomeric
formulas in patients with OTRD who present malnutrition could be very useful. Prior to the design of
a performance algorithm, we consider it would be necessary to carry out a literature review on the use
of oligomeric enteral nutrition formulas in patients with OTRD.
3. Review on the Use of Oligomeric Enteral Nutrition Formulas in Malnourish Patients
with OTRD
The mechanisms involved in the chemotherapy-associated diarrhea are not well explained, and
they vary according to the type of chemotherapy used, being more common after the administration of
topoisomerase inhibitors (irinotecan, the highest risk), methotrexate at high doses, fluoropyrimadines
(5-fluorouracil, capecitabine) or taxanes as docetaxel. It has been postulated that it could be due to
the damage of the intestinal crypts, or changes in the intestinal microflora, with an alteration of the
transport of fluids in the colon and a lower absorption of water. In addition, mucositis induced by
chemotherapy produces a malabsorption of nutrients that contribute to osmotic diarrhea. Most of the
literature is based upon clinical observations in which the number and consistency of bowel movements
are collected, as well as whether or not they are accompanied by blood, mucus and pain. On the other
hand, irradiation on the cells of the intestinal mucosa causes a loss of mucosal surface, with the loss of
intestinal permeability, motility and absorption of nutrients. It also facilitates the translocation of the
intestinal microflora, the appearance of ulcers, necrosis, mucous membrane bleeding and even more
serious complications, such as intestinal fistula.
The most characteristic clinical manifestation is diarrhea [50]. Lees clear are the mechanisms of
TKI-induced and immunotherapy-induced diarrhea, since it has not been widely studied yet, but
most of the hypotheses link this toxicity to mechanisms that are shared with chemotherapy-induced
diarrhea [7].
An oligomeric enteral nutrition diet can be a nutritional treatment of choice in the patient with
OTRD for its easy absorption, inhibition of pro-inflammatory cytokine production and maintenance of
mucosal integrity. There are very few published reviews on the efficacy of enteral peptide nutrition in
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patients with diarrhea associated with oncotherapy. We found a Cochrane review in patients with
radiotherapy, but the researcher was not able to perform meta-analysis due to the lack of studies [51].
Given the limited published evidence, we consider that a bibliographic review on the subject was
necessary prior to the preparation of the nutritional support algorithm in patients with OTRD.
For this review, we researched on-line databases PUBMED, MEDLINE, EMBASE and the Cochrane
library up to March 2019, using the following terms: ((Chemotherapy) or (radiotherapy)) and ((oral
mucositis) or (diarrhea) or (peptide diet) or (elemental diet) or (oligomeric diet)) in order to collect
potentially relevant articles. Animal, not clinical, trials and non-adult studies were excluded. Retrieved
articles were reviewed for relevance, duplicates were discarded, and the full text of all potentially
relevant articles was classified and assessed for inclusion using predetermined criteria. Only clinical
trials about oligomeric elemental or peptide enteral nutrition were screened. Reference lists of all of
the included articles were reviewed for additional possibly relevant citations. Further details about the
literature search process are provided in Figure 1. Relevant studies were identified [52–68], and their
results are summarized in Tables 2 and 3.
Nutrients 2018, 10, x FOR PEER REVIEW  12 of 37 
 
 
Figure 1. Flow chart describing the literature search process. 
Regarding the studies with oligomeric diets in oncological patients under treatment with 
radiotherapy [52–59] (Table 2), 998 patients were collected (476 in the intervention groups and 522 in 
the control groups). The three oldest studies [52–54] were conducted with Vivonex® without 
significant differences in the response to stool characteristics, or in the amount of weight lost. The 
next two studies to appear [55,56] were performed with Vital HNR®, detecting an improvement in 
the severity and duration of diarrhea in the group that took the enteral nutrition product. 
Subsequently, another study with 677 patients [57] shows a significant reduction in intestinal 
toxicity, the suppression of radiotherapy and weight improvement with an undefined elemental 
diet. But this is a study that is only a conference abstract, and does not define the type of oligomeric 
enteral nutrition used. The last study that we found which compares oligomeric diet with habitual 
diet is that of McGough et al. [58] that uses EO28®. It does not find improvement in gastrointestinal 
symptoms or nutritional status, because only 24% of patients take the product. Finally Feng Shao et 
al. [59] compares an oligomeric diet (Peptisorb®) with or without microorganisms and fish oil, with 
an improvement in abdominal pain, bloating and diarrhea. 
Table 2. Studies with oligomeric diet and Radiotherapy-induced oro-intestinal mucositis. 
Figure 1. Flow chart describing the literature search process.
Nutrients 2019, 11, 1888 8 of 20
Table 2. Studies with oligomeric diet and Radiotherapy-induced oro-intestinal mucositis.
Author, Year Type of Study Number Patients, Sex,Age (y) Disease Intervention Follow-Up Component Diet Object of Study Results Confounders
Brown [52]
1980
One single-centre
parallel group
unblinded RCT
68 patients (16 in control
group, 30 who adhered
to the ON diet and 21
who did not adhere to
the full period of
supplementation). Men
70%, 69–29y.
Mainly urological
tumours, with
many other types of
primary tumours.
Compare reduced fibre
diet (control) versus three
sachets of ON with a
reduced fibre diet.
During irradiation
Vivonex HN (Eaton
Lab): 900 kcal and 40 g
of mixed amino acids,
simple sugars, fats,
vitamins and mineral.
Reported weight and
stool frequency.
Mean stool frequency 4/d for all
three groups. Mean weight loss
was 1.6 kg, 0.5 kg and 1.7 kg
respectively.
Heterogeneous group.
Only means were
reported with no
measurement of
variance given
Foster [53]
1980
One single-centre
parallel group
unblinded RCT
32 patients (12 control
and 20 intervention).
75% male, 66y,
Carcinoma bladder,
prostate, uterus and
testis
Compare reduced fibre
diet (control) versus three
sachets of Vivonex HN
with a reduced fibre diet.
During irradiation
Vivonex HN (Eaton
Lab): 900 kcal and 40 g
of mixed amino acids,
simple sugars, fats,
vitamins and mineral.
Investigate the
metabolic effects of
therapeutic irradiation
in different diet
planning
Weight loss similar (1.4 vs. 1 Kg).
No differences in metabolic and
hormonal determinations.
Few of the patients were
underweight at the start
of treatment.
Beer [54] 1985
One single-centre,
prospective cohort
study
8 patients (7 female, 1
male). 3 control and 5
intervention.
Gynecologic or
testicular
malignancy
Compare oral diet versus
vivonex-HN and
Criticare-HN
Five days
Vivonex HN (Eaton
Lab): 900 kcal and 40 g
of mixed amino acids,
simple sugars, fats,
vitamins and mineral.
Criticare HN: 900 kcal
and 38 g of protein
hydrolyzed casein,
amino acids
Investigate weight
and stool frequency
The mean daily fecal weight and
energy were decreased
Few patients, The
follow-up is very short
McArle [55]
1986
One single-centre
parallel group
unblinded RCT
56 patients (32 control
and 24 intervention).
75% men, 65y
Invasive bladder
cancer
Control: regular hospital
diet or TPN during RT.
Intervention: 1600–2000
Kcal during 3 days before
RT and during RT
supplementation with ON
continuous feeding
nasoduodenal tube or by
mouth.
During irradiation
Vital HNR (Ross Lab):
Partially hy drolyzed
whey, meat, soy,
hydrolyzed cornstarch
and sucrose, safflower
oil and MCT.
Investigate whether
elemental diet could
prophylaxis intestinal
injury by
radiotherapy.
The severity of the diarrhea in
control was significantly greater.
No bloody diarrhea. Positive
nitrogen balance. Biopsy ileal
normal mucosa morphologia and
maintenance enzyme activity.
Control group is
retrospective dates.
Craighead
[56] 1998
One single-centre
uncontrolled phase
II prospective
cohort study
61 patients (16
intervention group and
a cohort of 45 patients
(control)
primary cervical
and endometrial
cancer patients
Intervention with ON.
Both cohorts diet restricted
lactose, low fibre (12g
daily), moderate fat intake
(< 30% calories), adequate
protein and carbohydrate.
Intake of fruits, caffeine
and other bowel
stimulants restricted.
From three days
before the start of
radiotherapy to the
last day of
radiotherapy
Vital HNR: Partially hy
drolyzed whey, meat,
soy, hydrolyzed
cornstarch and sucrose,
safflower oil and MCT.
Assess compliance
elemental
supplements and
preliminary assess of
the efficacy.
Intervention vs. control: RTOG
grade (55% vs. 15%, p < 0.001);
Mean (SD) duration of diarrhoea
during treatment was 5.85 days
(4.44) vs. 12.2 days (6.95).
The study was small
and not powered for GI
symptoms or weight.
Neither randomised nor
controlled. Diarrhoea
was not clearly defined.
It was not clear whether
there were any
differences between
baseline characteristics
of the cohorts.
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Table 2. Cont.
Author, Year Type of Study Number Patients, Sex,Age (y) Disease Intervention Follow-Up Component Diet Object of Study Results Confounders
Capirci [57]
2000
Conference abstract
of a multicentre
RCT
677 patients (332
intervention group and
345 control group).
439 with primary
rectal cancer, 228
primary uterine
cancer and 10
prostate cancer.
Natural diet plus
elemental diet compared
with standard diet
(control)
Not defined OD Not defined.
The outcomes were
RTOG score and
change in weight pre-
and
post-radiotherapy.
Toxicity significantly less in
intervention group. 12 vs. 44
patients required a break in
radiotherapy due to GI toxicity in
the intervention and control group.
The total numbers with each grade
of diarrhoea were not reported.
Weight response significant
differences intervention vs.
control: grade 1 toxicity (+1 vs. 0
Kg ), grade 2 (0 vs. −1.3 Kg) and
grade 3–4 (−5.5 vs. −4 Kg)
There is no full report.
Available data limited.
It was not clear whether
change in weight
reported was mean
change in weight and no
measure of variance was
reported. The statistical
methods not described.
Heterogeneous group.
McGough [58]
2008
One single-centre
parallel group
unblinded RCT
50 patients (29 women
and 21 men).
Intervention (25 people),
Control (25 people)
Gynaecological,
urological or lower
GI malignancy
Control: habitual diet.
Intervention: Replace one
meal per day (33% of daily
calories) with ON.
The first three weeks
of radiotherapy.
EO28 Extra (SHS Lab):
85 Kcal, 14% protein,
35% fats (MCT 35%),
52% carbohydrate.
Primary outcome was
GI symptoms at week
five using IBDQB
index. Other
outcomes: GI
symptoms using VIQ
and RTOG toxicity
grade, Weight and
BMI, and Faecal
Calprotectin
GI symptoms increased between
baseline and both weeks three and
five (P value < 0.001) in both
groups. VIQ scores improved for
patients in the intervention group
comparing week 10 versus week
five (P value < 0.001) but not in the
control group (P value = 0.06).
there was poor compliance with
the intervention (6/25, 24%) and no
improvement was seen in terms of
GI symptoms or nutritional status.
Different baseline
characteristics in terms
of primary tumour and
treatment regimen, The
median intake of
elemental diet, was
lower than the
prescribed volume
required to provide 33%
of caloric requirement.
Six patients were
non-compliant
Feng Shao
[59] 2013
One single-centre
parallel group
unblinded RCT
46 patients (24 treatment
group and 22 control
group,). (22 males and
24 females), 60.2y.
Abdominal tumor
with post-radiation
enteritis
Intervention: Peptisorb
plus triple live
microorganismal tablets,
L-Glutamine enteric
capsule and fish oil
capsule. Control:
Peptisorb only
Whenrceiving
radiotherapy or
within 3 weeks
post-radiotherapy
Peptisorb: ON 16 %
protein (85 % small
peptides and 15 %
amino acid peptide), 9 %
fat and 75 %
carbohydrates.
Microorganismal agent
comprised
Bifidobacterium,
lactobacillus and
Streptococcus
thermophilus.
Investigate the effect
of microbial immune
enteral nutrition by
microecopharmaceutics
and deep sea fish oil
and glutamine and
Peptisorb on the
patients with acute
radiation enteritis in
bowel function and
immune status.
Intervention group: Abdominal
pain, bloating and diarrhea was
better than the control group (P
values were 0.018, 0.04 and 0.008
after 7 days; P values were 0.018,
0.015 and 0.002 after 14 days); and
the cellular immune parameters
were better than the control
group(p = 0.008, p = 0.039,
p = 0.032);
Heterogeneous group.
Difficult know if the
results are because,
mirocoorganism,
glutamin o or fish oil.
Both use ON.
ON: Oligomeric nutrition; GI: Gastrointestinal; RTOG: Radiation Therapy Oncology Group criteria; VIQ: Vaizey Incontinence Questionnaire; TPN: Total parenteral nutrition.
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Table 3. Studies with oligomeric diet and chemotherapy-induced oro-intestinal mucositis.
Author, Year Type of Study Numbrer patientes,Sex, Age (y). Disease Intervention Follow-Up Component Diet Object of Study Results Confounders
Ishikawa [60]
2016
Randomized, open
label, phase 2
clinical trial
33 patients (17 azulene
and 16 OD)
Primarysquamous
cell carcinoma of
the esophagus who
were scheduled to
undergo
chemotherapy or
chemoradiotherapy
Randomized to receive
either azulene oral rinse
(Arm 1) or OD (Arm 2)
During the
treatment cycle (4
weeks).
Elental® (Ajinomoto
Pharmaceutical) (80 g/
300 kcal amino-acid-rich,
fat free, elemental diet)
Examine the
preventive effects of
OD on oral mucositis
and sarcopenia
progression during
chemo (chemoradio)
therapy for
esophageal cancer
OD tended to reduce the incidence of oral
mucositis (Arm 1, 23.5% and Arm 2, 12.5%),
but there was no statistically significant
difference. The average body mass index and
body fat mass decreased significantly in both
groups. Lean body mass was reduced in
Arm 1, but was increased in Arm; the relative
change of lean body mass after the treatment
was significant between Arm 1 and Arm 2
(p = 0.007). The incidence of diarrhea was
greater in Arm 2 than in Arm 1 (31.3 and
11.8%, respectively), and was grade 2 or less.
Single institution,
small patient
number
Tanaka [61]
2016
One single-centre
parallel group
unblinded RCT
30 patients (10 control,
10 Glutamin group and
10 Glutamin plus OD).
90% female. Age
68–75y.
Esophageal cancer
Control (no treatment),
Gln group (oral 8910 mg
Gln/day), Gln plus OD
group.
Oral administration
of Glutamin and OD
began 1 week before
chemotherapy and
continued during
treatment.
Elental® (Ajinomoto
Pharmaceutical) (80 g/
300 kcal amino-acid-rich,
fat free, elemental diet)
Investigate the effect
of glutamine and OD
chemotherapy-inducOD
oral mucositis in
esophageal cancer
patients
The incidence of grade ≥2 oral mucositiswas
60% in control group, 70 % in Glutamin
group, and 10 % in Glutamin plus OD group.
The percentage of change in body weight and
diamine oxidase activity from before
chemotherapy was higher in Glutamin plus
OD group than control group.
Small number of
patients. Effects not
well explained.
Morishita [62]
2016
One single-centre
prospective cohort
study
73 patients (23
autologous HSCT and
50 allogeneic). 21
Control and 52
intervention. Age 47y
(17–67). Male 50%
intervention and 70%
control.
hematopoietic stem
cell transplantation
(HSCT)
The first 21 patients did
not receive OD and in the
successive 52 patients
received OD
Oral OD was started
before conditioning
and was continued
until 28 days after
transplantation
Elental® (Ajinomoto
Pharmaceutical) (80 g/
300 kcal amino-acid-rich,
fat free, elemental diet)
The primary endpoint:
hospitalization period.
The secondary
endpoint: occurrence
of oral mucositis,
nausea, diarrhea and
fever.
The median hospitalization period was
significantly shorter in intervention group
compared to control (34 days vs. 50 days;
p = 0.007). Grade 3–4 oral mucositis occurred
less in intervention than control (25% vs.
48%; p = 0.06). There were no significant
differences in the use of opioid agents, grade
3–4 diarrhea, or grade 3–4 nausea, for both
frequency and duration
Single institution,
small patient
number,
prospective cohort
study and included
both autologous
and allogeneic
patients.
Ogata [63]
2016
One single-centre
prospective pilot
study
22 patients (10 male and
12 Female) 67y
Metastatic
colorectal cancer
patients after
developing grade
1–3 oral mucositis.
The OD Elental® (80 g/300
kcal or more per day) was
given perorally in addition
to normal oral ingestion,
together with
chemotherapy in each
course lasting 2 to 3 weeks
(on days 1–14 or days
1–21).
Introduction of OD
after developing
grade 1–3
oralmucositis
Elental® (Ajinomoto
Pharmaceutical) (80 g/
300 kcal amino-acid-rich,
fat free, OD)
Evaluate the
preventive effects of
Elental®, on
chemotherapy-induced
oral mucositis in
colorectal cáncer.
The maximum grade of oral mucositis
decreased in 18 of the 22 patients during the
first treatment course with Elental®
(p = 0.0002) and in 20 of the 22 patients in the
second course (p < 0.0001).
Single institution,
small simple size,
no control group.
Harada [64]
2016
One single-centre
retrospective study
74 patients (37
intervention and 37
control group)
Oral squamous cell
carcinoma (OSCC)
patients who
underwent
radiation
with/without
chemotherapy
Recorded data on a daily
basis and compared the
data from 37 patients who
received OD (intervention
group) with those from 37
patients who did not
receive OD (the control
group)
During the
treatment period (6
weeks).
Elental® (Ajinomoto
Pharmaceutical)
(80 g/300 kcal
amino-acid-rich, fat free,
elemental diet)
Evaluate the
preventive effects of
Elental®, on
radiotherapy- or
chemoradiotherapy-
induced mucositis in
OSCC patients.
Most of the patients who consumed OD
suffered from a lower degree of mucositis
compared to control group. OD was
associated with a significantly improved rate
of completion of chemoradiation (no
interruption). There was no significant
difference between OD group and control
group in terms of mean change of body
weight or total protein and albumin levels in
blood serum before and after
chemoradiation.
Single institution.
Retrospective
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Table 3. Studies with oligomeric diet and chemotherapy-induced oro-intestinal mucositis.
Author, Year Type of Study Numbrer patientes,Sex, Age (y). Disease Intervention Follow-Up Component Diet Object of Study Results Confounders
Okada [65]
2017 RCT
22 patients (11
intervention and 11
control)
Esophageal cancer
undergoing
chemotherapy
Intervention: Elental (one
pack per day) for 14 days
and control not receiving
Elental during
chemotherapy
During
chemotherapy
Elental® (Ajinomoto
Pharmaceutical)
(80 g/300 kcal
amino-acid-rich, fat free,
elemental diet)
Evaluate the influence
of elemental diet on
chemotherapy-induced
oral mucositis and
diarrhea.
The distribution of the maximum severity of
oral mucositis showed a statistically
significant reduction in the Elental group
(p = 0.020). Regarding diarrhea, no difference
was observed between the two groups.
Single institution,
small sample size,
most patients in the
Elental group did
not receive the same
dose of Elental.
Tanaka [66]
2018
Prospective
multi-center
feasibility study
19 patients (males
100%), 68y (37–75y).
Stage II/III
esophageal
squamous cell
carcinoma or
adenocarcinoma
Orally administerOD OD
2 packs (160 g/day) during
chemotherapy.
2 cycles of
chemotherapy
Elental® (Ajinomoto
Pharmaceutical)
(80 g/300 kcal
amino-acid-rich, fat free,
elemental diet)
The primary was the
compliance of an
orally administerOD
OD 2 packs. The
secondary endpoints
were the incidence of
oral mucositis; the rate
of weight fluctuation;
plasma diamine
oxidase activity; the
turnover rate of
plasma proteins and
adverse events.
70% patients were able to complete the orally
administered OD (160 g/day). The incidence
of grade ≥ 2 oral mucositis in the OD
completion group (15.4%:, 2 of 13 patients)
was significantly lower than that in the
non-completion group (66.7%, 4 of 6 patients)
(p = 0.046). The grade 3 adverse events were:
fatigue (15%), fever (15%), anorexia (15%);
diarrhea (10%).
Small sample size,
No control group,
Harada [67]
2019
One single-centre
prospective study
50 patients (25 with OD
and 25 control without).
Males 70%.
Oral squamous cell
carcinoma patients,
who received
radiation (60-70 Gy)
with/without
chemotherapy.
Intervention: 1 bottle/day
of OD (80 g, 300 kcal)
orally. Control without
OD.
The median follow
up period was 23
(8–37) months
Elental® (Ajinomoto
Pharmaceutical)
(80 g/300 kcal
amino-acid-rich, fat free,
elemental diet)
Evaluate the
preventive effects of
OD on radiotherapy-
or
chemoradiotherapy-
induced mucositis in
oral squamous cell
carcinoma patients
Multivariate analysis indicated that most of
the patients who received Elental® suffered
from a lower degree of mucositis and
showed significantly improved rate of
completion of chemoradiation (no
interruption) compared to the control group.
There was a significant difference between
the Elental® group and the control group in
mean change of C-reactive protein levels in
blood serum; however, there was no
significant difference in mean change of body
weight and total protein level in blood serum
before and after chemoradiation. Diarrhea
were no determinated.
Single institution,
Toyomasu
[68] 2019
One single-centre
randomizOD
open-label study
22 patients (11 control
and 11 intervention).
Ages ranged from 59 to
80y.
Patients who
underwent
adjuvant
chemotherapy for
gastric cancer
One pack of OD per day During adjuvantchemotherapy
Elental® (Ajinomoto
Pharmaceutical)
(80 g/300 kcal
amino-acid-rich, fat free,
elemental diet)
Whether an oral OD
prevents
chemotherapy
associated oral
mucositis and body
weight loss.
The incidence of oral mucositis was
significantly lower in the treatment group
(9.1 %) than in the control group (27.3%). The
median body weight loss in the treatment
group was significantly smaller than that in
the control group (p = 0.015). The treatment
group was significantly associated with high
cumulative S-1 continuation rates (log-rank
p = 0.047). No differences in diarrhea
between groups.
Single-institutional
study with a small
sample size
OD: Oligomeric diet.
Nutrients 2019, 11, 1888 12 of 20
Regarding the studies with oligomeric diets in oncological patients under treatment with
radiotherapy [52–59] (Table 2), 998 patients were collected (476 in the intervention groups and
522 in the control groups). The three oldest studies [52–54] were conducted with Vivonex® without
significant differences in the response to stool characteristics, or in the amount of weight lost. The
next two studies to appear [55,56] were performed with Vital HNR®, detecting an improvement in the
severity and duration of diarrhea in the group that took the enteral nutrition product. Subsequently,
another study with 677 patients [57] shows a significant reduction in intestinal toxicity, the suppression
of radiotherapy and weight improvement with an undefined elemental diet. But this is a study that is
only a conference abstract, and does not define the type of oligomeric enteral nutrition used. The last
study that we found which compares oligomeric diet with habitual diet is that of McGough et al. [58]
that uses EO28®. It does not find improvement in gastrointestinal symptoms or nutritional status,
because only 24% of patients take the product. Finally Feng Shao et al. [59] compares an oligomeric
diet (Peptisorb®) with or without microorganisms and fish oil, with an improvement in abdominal
pain, bloating and diarrhea.
Regarding chemotherapy-induced intestinal mucositis [60–68] (Table 3), all the studies we have
found used the same oligomeric formula of enteral nutrition (Elental®). In total there are 345 patients,
of whom 203 were treated with this oligomeric enteral nutrition, and the rest are controls without
enteral nutrition. In summary, the main objective of the studies is the effect of this type of oral
nutritional supplement on oral mucositis in patients with chemotherapy. In all of the studies [60–68]
oral mucositis improves, while the rest of the outcomes show different results. Only one study
observes improvement in controls on body weight [68], while two others do not find differences [64,67],
although in another they find improvement in lean body mass [60]. With regards to the response
of diarrhea to this supplementation, the majority of studies do not find differences compared to the
control group [62,65,66,68]. Despite these poor results, some authors note that hospitalization time
decreases [62], and there are fewer cases in which chemotherapy should be stopped due to its side
effects [64,67].
The results of the studies that we have reviewed are very heterogeneous, both in the type of
patients, as well as the type of cancer to be treated, in the chemotherapy/radiotherapy dose and in the
enteral nutrition formula used, thus the difficulty to draw conclusions. It is not known what proportion
of normal diet should be replaced by oligomeric formula to confer the most benefit. In addition to the
proportion determination, it is likely that the formulation of the oligomeric diet is important. Similarly,
the proportion of fat derived from medium chain triglycerides is likely to be impactful, as this will
influence the degree of pancreatic and biliary secretions, both of which may exacerbate damage to the
intestinal mucosa [45].
Although oligomeric enteral nutrition formulas have not shown homogeneous efficacy in all
studies, we do not have effective pharmacological treatments for these patients [69,70]. At present,
the recombinant keratinocyte growth factor-1, palifermin, is thought to be a promising agent for
the management of oral mucositis associated with cancer treatment. Regardless of its usefulness in
decreasing oral mucositis, the safety of this growth factor in cancer patients remains unclear, and it is
expensive compared to other types of therapies for oral mucositis [71]. Compared to other treatment
options available for intestinal mucositis in cancer patients, oligomeric enteral nutrition could be
an attractive agent, because it is neither costly, nor a growth factor treatment, such as palifermin.
Furthermore, no side effects of enteral nutrition have been reported thus far. However, only a few
published reports are available on the efficacy of oligomeric enteral nutrition for the treatment of
chemo-radiotherapy-induced intestinal mucositis (Tables 2 and 3).
Harada et al. [67] show that administration of an oligomeric enteral formula was associated with
a suppressed expression of protein C reactive. According to in vitro data from the same group, this
oligomeric enteral formula could successfully downregulate the expression of inflammatory cytokines
in the immortalized human keratinocyte cell line HaCaT [72]. In this way, it might suppress protein C
reactive expression via the downregulation of inflammatory cytokines. Harada et al. also showed
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previously that this oligomeric enteral formula can treat mucositis and dermatitis by accelerating
mucosal and skin recovery through FGF2 induction and reepithelization in vivo [73].
The Tanaka group have studied and measured the intestinal mucosal integrity on the basis of
plasma diamine oxidase activity. In a recent study they found that the integrity of the intestinal mucosa
tends to be maintained in the enteral oligomeric nutrition group [66]. Previous studies have shown that
amino acids themselves can protect the mucosa and have anti-inflammatory effects [74]. Furthermore,
the administration of an oligomeric enteral nutrition during chemotherapy has been reported to have
the potential prevent mucositis [61,63]. In these studies authors group observe that body weight is
maintained in the intervention group, in front of weight loss in a control group.
It could be explained, because oligomeric enteral nutrition with Glutamine may have maintained
gastrointestinal mucosal integrity, and in this way, maintain nutrient absorption. Furthermore,
amino acids may be more suitable than proteins to provide nutrients, as proteins require digestion.
Fijlstra et al. [75] observe that enteral administration of amino acid mixtures enable normal amino acid
absorption in patients with mucositis.
Enteral oligomeric nutrition could offer mechanisms of protection of the intestinal mucosa. It
might increase and stabilize the intestinal bacterial microbiota [76]. In addition, enteral oligomeric
nutrition contains amino acids instead of whole protein. These amino acids could have less antigenic
power, and thus have less pro-inflammatory effect for the intestinal mucosa [48]. Therefore, this type
of oligomeric enteral nutrition, in addition to providing the necessary nutrients in a malnourished
patient, could have a non-negligible, anti-inflammatory effect.
However, in the clinical practice guidelines of the different scientific societies, there are dietary
recommendations for the nutritional treatment of OTRD, and in some cases these recommend the use
of oligomeric enteral nutrition [22,27], but do not offer protocols of action with oral enteral nutrition.
Based on these nutritional recommendations of the scientific societies and the publications
reviewed with oligomeric enteral nutrition formulas, we propose a protocol of action before the
appearance of OTRD.
4. Nutritional Support Algorithm in Patients with OTRD
A direct effect of OTRD is that malabsorption and therefore the risk of malnutrition in these patients
is very high. An oligomeric enteral nutrition diet can be the nutritional treatment of choice in patients
with OTRD for its easy absorption. Enteral oligomeric nutrition may also have anti-inflammatory effects,
change the microbiota, and also lower antigenic effects that protect the oro-intestinal mucosa [67,68].
Its main effect, however, is to maintain the nutritional status of the patient, and to better withstand
oncological treatment.
The algorithm of action that we propose covers two aspects: On the one hand, the nutritional
assessment of the patient with regard to its nutrient reserve, and on the other hand, the intestinal
capacity to absorb nutrients (Figure 2).
The first step in the algorithm we propose is the nutritional assessment of the OTRD oncologic
patient. These patients display a high risk of malnutrition, suffering from cancer cachexia, and under
aggressive oncological treatment they present OTRD, a side effect causing malabsorption [10]. There
are multiple nutritional assessment tests specific to the patient with cancer [15], the majority resulting
in a handful of indicators such as: Non-volitional weight loss, low body mass index or reduced muscle
mass, reduced food intake or assimilation, and inflammation or disease burden. These criteria have
been gathered in a recent consensus by the Global Leadership Initiative on Malnutrition (GLIM),
composed by representatives of several of the leading global clinical nutrition societies, and are those
that we recommend [77].
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The second step is the assessment of the functional capacity of the patient’s intestine. In this step,
the presence of OTRD would indicate the intestinal inability to absorb nutrients and the loss of fluids
and electrolytes.
With these two aspects evaluated, we could encounter a case within the most advantageous
diagnosis of a well-nourished patient without diarrhea, in which only regular dietary measures to
prevent the risk of malnutrition would be necessary. On the opposite side of the spectrum, we would
find a patient with severe malnutrition and diarrhea, where a nutritional treatment using exclusive
enteral nutrition with an oligomeric formula would be required. Thus, the therapeutic possibilities
will vary from less to more complexes, depe ding upon the patient’s initial nutritional situation and
the exis ence of OTRD. These cou ses of treatment will range from the usual dietary recommendations,
to supplementation with oral oligomeric enteral nutrition, omplete enteral nutritio with oligomeric
formula and th to finally total pare ter l nutr tion.
After an initial valuation and nutritional therapy, a reassessment after 5–7 days of the
nutritional treatment effectiveness, both OTRD responses and nutritional parameters, is recommended.
Consequently, if symptoms do not subside, or the patient continues to deteriorate, it is recommended
to move to the next therapeutic step.
5. Conclusio s
Oncology therapies cause frequently digestive toxicity, such as nausea, vomiting, mucositis and
diarrhea. OTRD and malnutrition tend to manifest together in the oncological patient as a consequence
of the disease itself, or because of the treatments that are administered. Regardless of the cause of the
OTRD, it is essential to carry out a nutritional treatment that facilitates absorption, reduces waste and
digestive symptoms, and contributes to the prevention of malnutrition, which is so frequent in the
oncological population. Formulas containing peptides and medium chain triglycerides can facilitate
absorption in case of, e.g., malabsorption or short bowel syndrome. Standard OTRD management
guidelines are widely published. Most of the treatments that appear in the guidelines are focused upon
the treatment of OTRD, but very few consider the adequate nutritional support in order to prevent
malnutrition. Some guidelines recommend the use of oligomeric enteral nutrition, but do not offer any
protocols of action with oral enteral nutrition. The results of the studies that we have reviewed are
very heterogeneous, so it is very difficult to draw conclusions. Nevertheless, we consider that the use
of nutritional supplements with oligomeric formulas in patients with OTRD who present malnutrition
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could be very useful. Because enteral oligomeric nutrition could offer protective mechanisms for the
intestinal mucosa, we propose a protocol of action before the appearance of OTRD.
Although this review is based mainly upon studies focused on chemotherapy and radiotherapy,
we think that our conclusions and recommendations would most likely be widely applied to the
management of malnutrition associated to new anticancer agents, despite the paucity of data about
their management.
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